Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 in Monogenic IL-18 Driven Autoinflammatory Diseases
NCT04641442Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Oct 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in NLRC4-associated autoinflammatory syndrome, X-linked inhibitor of apoptosis protein deficiency and necrotizing enterocolitis (NEC) comparing MAS825 with Placebo (2 arms). Primary endpoint: Occurrence of disease flare up to 6 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
MAS825
03
Conditions
NLRC4-associated autoinflammatory syndromeX-linked inhibitor of apoptosis protein deficiencynecrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT04641442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641442.